In patients with developmental and epileptic encephalopathy with genetic etiology, KD is more effective in patients with SCN1A, KCNQ2, STXBP1, and SCN2A mutations rather than patients with CDKL5 mutations (7). This evidence concerns the gene SCN2A and developmental and epileptic encephalopathy.